Mika Yamauchi
Overview
Explore the profile of Mika Yamauchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yamamoto M, Yamauchi M, Sugimoto T
PLoS One
. 2019 Sep;
14(9):e0222571.
PMID: 31525243
Background: An assessment of bone strength based on bone mineral density (BMD) underestimates the risk of fracture in patients with diabetes mellitus (T2DM). However, using the trabecular bone score (TBS)...
12.
Noda M, Ishii K, Yamauchi M, Oyama H, Tadokoro T, Maenaka K, et al.
J Pharm Sci
. 2019 Mar;
108(7):2323-2333.
PMID: 30851343
Antibody aggregates are a potential risk for immunogenicity; therefore, rational approaches to improve associated aggregation properties need to be developed. Here, we report the amino acid region responsible for aggregation...
13.
Yamauchi M, Sugimoto T
Clin Calcium
. 2019 Mar;
29(3):329-336.
PMID: 30814378
Wnt signaling is known to be involved in metabolic bone disorders. Serum levels of sclerostin, a bone-specific protein that inhibits Wnt signaling, have been investigated in a variety of metabolic...
14.
Takeno A, Yamamoto M, Morita M, Tanaka S, Kanazawa I, Yamauchi M, et al.
BMC Endocr Disord
. 2019 Feb;
19(1):25.
PMID: 30782163
Background: Immune checkpoint inhibitors including nivolumab, an anti-programmed cell death protein 1 antibody, are recently developed cancer immunotherapy agents. Immune checkpoint inhibitors are known to cause autoimmune-related side effects including...
15.
Yamauchi M
Clin Calcium
. 2018 Nov;
28(12):1635-1640.
PMID: 30487328
Glucocorticoid(GC)excess is one of the most common causes of secondary osteoporosis, which can be associated with a disease(GC excess due to Cushing's syndrome)or with a treatment(GC medications). In addition to...
16.
Yamauchi M
Clin Calcium
. 2018 Oct;
28(10):66-1364.
PMID: 30269118
A variety of epidemiological studies and meta-analyses have shown that vitamin D insufficiency or deficiency not only affects bone and mineral metabolism, but is also linked to sarcopenia, metabolic diseases...
17.
Otani H, Notsu M, Koike S, Morita M, Yamamoto M, Yamauchi M, et al.
Thyroid Res
. 2018 May;
11:4.
PMID: 29785209
Background: The thyroid gland is resistant to microbial infection, because of its organ characteristics such as encapsulation, iodine content, and rich blood supply. Therefore, acute suppurative thyroiditis (AST), as a...
18.
Yamauchi M, Sugimoto T
Clin Calcium
. 2017 Oct;
27(11):1561-1569.
PMID: 29074828
Numerous epidemiological studies and meta-analyses have indicated that there is a link between Vitamin D insufficiency/deficiency and metabolic disorders such as type 1 and type 2 diabetes mellitus as well...
19.
Yamauchi M, Sugimoto T
Clin Calcium
. 2017 Jul;
27(8):1067-1073.
PMID: 28743842
Fracture risk in patients with secondary osteoporosis, which includes glucocorticoid-induced osteoporosis, was found to be higher than the fracture risk predicted by decreased bone mineral density. Moreover, a large scale...
20.
Yamauchi M, Sugimoto T
Nihon Naika Gakkai Zasshi
. 2017 May;
104(11):2414-20.
PMID: 28530357
No abstract available.